{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Solid+Neoplasm&page=107",
    "query": {
      "condition": "Advanced Solid Neoplasm",
      "page": 107
    },
    "page_size": 10
  },
  "pagination": {
    "page": 107,
    "page_size": 10,
    "total_count": 3389,
    "total_pages": 339,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Solid+Neoplasm&page=108&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Solid+Neoplasm&page=106&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-16T19:19:00.254Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04628780",
      "title": "Study to Test the Safety and Tolerability of PF-07209960 in Advanced or Metastatic Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non-small-cell Lung Cancer",
        "Squamous Cell Carcinoma of the Head and Neck",
        "Renal Cell Carcinoma",
        "Urothelial Carcinoma",
        "Colorectal Carcinoma",
        "Ovarian Carcinoma"
      ],
      "interventions": [
        {
          "name": "PF-07209960",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 37,
      "start_date": "2020-12-16",
      "completion_date": "2023-05-26",
      "has_results": true,
      "last_update_posted_date": "2024-07-29",
      "last_synced_at": "2026-11-16T19:19:00.254Z",
      "location_count": 13,
      "location_summary": "Duarte, California • Los Angeles, California • Santa Monica, California + 3 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04628780"
    },
    {
      "nct_id": "NCT06299839",
      "title": "PAS-004 in Patients With Advanced Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "RAS Mutation",
        "NF1 Mutation",
        "RAF Mutation",
        "Advanced Solid Tumors"
      ],
      "interventions": [
        {
          "name": "PAS-004 Capsules",
          "type": "DRUG"
        },
        {
          "name": "PAS-004 Tablets",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pasithea Therapeutics Corp.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 83,
      "start_date": "2024-02-29",
      "completion_date": "2027-09",
      "has_results": false,
      "last_update_posted_date": "2026-10-30",
      "last_synced_at": "2026-11-16T19:19:00.254Z",
      "location_count": 2,
      "location_summary": "San Antonio, Texas • Fairfax, Virginia",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        },
        {
          "city": "Fairfax",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06299839"
    },
    {
      "nct_id": "NCT01357330",
      "title": "Oral SAR245408 (XL147) and Oral MSC1936369B in Patients With Locally Advanced or Metastatic Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumors"
      ],
      "interventions": [
        {
          "name": "SAR245408 (XL147)",
          "type": "DRUG"
        },
        {
          "name": "MSC1936369B",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2011-05",
      "completion_date": "2012-06",
      "has_results": false,
      "last_update_posted_date": "2016-04-01",
      "last_synced_at": "2026-11-16T19:19:00.254Z",
      "location_count": 3,
      "location_summary": "Boston, Massachusetts • Nashville, Tennessee",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01357330"
    },
    {
      "nct_id": "NCT04739293",
      "title": "Study of ON 123300 in Patients With Advanced Cancer",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumors, Adult"
      ],
      "interventions": [
        {
          "name": "ON123300",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Traws Pharma, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 36,
      "start_date": "2021-05-13",
      "completion_date": "2024-10",
      "has_results": false,
      "last_update_posted_date": "2023-12-07",
      "last_synced_at": "2026-11-16T19:19:00.254Z",
      "location_count": 3,
      "location_summary": "Grand Rapids, Michigan • Greenville, South Carolina • Dallas, Texas",
      "locations": [
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        },
        {
          "city": "Greenville",
          "state": "South Carolina"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04739293"
    },
    {
      "nct_id": "NCT02665416",
      "title": "Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of Selicrelumab (RO7009789) With Vanucizumab or Bevacizumab in Participants With Metastatic Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced/Metastatic Solid Tumors"
      ],
      "interventions": [
        {
          "name": "Selicrelumab",
          "type": "DRUG"
        },
        {
          "name": "Vanucizumab",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 94,
      "start_date": "2016-01-25",
      "completion_date": "2019-10-30",
      "has_results": false,
      "last_update_posted_date": "2020-04-07",
      "last_synced_at": "2026-11-16T19:19:00.254Z",
      "location_count": 5,
      "location_summary": "Los Angeles, California • Denver, Colorado • New Haven, Connecticut + 2 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02665416"
    },
    {
      "nct_id": "NCT03027128",
      "title": "QUILT-3.028: Study of haNK™ for Infusion in Subjects With Metastatic or Locally Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumor"
      ],
      "interventions": [
        {
          "name": "haNK™ for Infusion",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "ImmunityBio, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 6,
      "start_date": "2017-08-02",
      "completion_date": "2019-05-06",
      "has_results": true,
      "last_update_posted_date": "2024-11-20",
      "last_synced_at": "2026-11-16T19:19:00.254Z",
      "location_count": 1,
      "location_summary": "El Segundo, California",
      "locations": [
        {
          "city": "El Segundo",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03027128"
    },
    {
      "nct_id": "NCT05904236",
      "title": "Safety and Tolerability of Intravenous Administration of ICVB-1042",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Patients With Advanced Solid Tumors"
      ],
      "interventions": [
        {
          "name": "Treatment with ICVB-1042 administered intravenously",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "IconOVir Bio",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 17,
      "start_date": "2023-06-01",
      "completion_date": "2024-12-20",
      "has_results": false,
      "last_update_posted_date": "2025-04-08",
      "last_synced_at": "2026-11-16T19:19:00.254Z",
      "location_count": 10,
      "location_summary": "San Marcos, California • Detroit, Michigan • New York, New York + 7 more",
      "locations": [
        {
          "city": "San Marcos",
          "state": "California"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        },
        {
          "city": "Huntersville",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05904236"
    },
    {
      "nct_id": "NCT04526509",
      "title": "Master Protocol to Assess Safety and Dose of First Time in Human Next Generation Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Advanced Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neoplasms"
      ],
      "interventions": [
        {
          "name": "GSK3901961",
          "type": "DRUG"
        },
        {
          "name": "GSK3845097",
          "type": "DRUG"
        },
        {
          "name": "GSK4427296",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Adaptimmune",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2020-12-21",
      "completion_date": "2023-06-08",
      "has_results": true,
      "last_update_posted_date": "2024-11-26",
      "last_synced_at": "2026-11-16T19:19:00.254Z",
      "location_count": 9,
      "location_summary": "Jacksonville, Florida • Atlanta, Georgia • Westwood, Kansas + 5 more",
      "locations": [
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Westwood",
          "state": "Kansas"
        },
        {
          "city": "Lexington",
          "state": "Kentucky"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04526509"
    },
    {
      "nct_id": "NCT00879684",
      "title": "Safety And PK Study Of CVX-060 In Patients With Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumors",
        "Neoplasms",
        "Carcinoma",
        "Cancer",
        "Malignancy"
      ],
      "interventions": [
        {
          "name": "CVX-060",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 34,
      "start_date": "2008-01",
      "completion_date": "2011-04",
      "has_results": true,
      "last_update_posted_date": "2015-01-26",
      "last_synced_at": "2026-11-16T19:19:00.254Z",
      "location_count": 4,
      "location_summary": "Scottsdale, Arizona • Santa Monica, California • Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00879684"
    },
    {
      "nct_id": "NCT07223047",
      "title": "A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Solid Malignancies",
        "Non-small Cell Lung Cancer (NSCLC)",
        "Colorectal Cancer (CRC)",
        "Pancreatic Ductal Adenocarcinoma (PDAC)"
      ],
      "interventions": [
        {
          "name": "BMS-986523",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Nab-Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Cetuximab",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 252,
      "start_date": "2025-11-25",
      "completion_date": "2028-10-13",
      "has_results": false,
      "last_update_posted_date": "2026-05-28",
      "last_synced_at": "2026-11-16T19:19:00.254Z",
      "location_count": 4,
      "location_summary": "Baltimore, Maryland • San Antonio, Texas • West Valley City, Utah + 1 more",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        },
        {
          "city": "West Valley City",
          "state": "Utah"
        },
        {
          "city": "Fairfax",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07223047"
    }
  ]
}